• 1
    Liu J, Yang HL, Lee MH, Lu SN, Jen CL, Wang LY, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 139: 474-482.
  • 2
    McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25( Suppl 1): 3-8.
  • 3
    Beasley RP, Hwang LY, Lee GCY, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus-infections with hepatitis B-immune globulin and hepatitis-B vaccine. Lancet 1983; 2: 1099-1102.
  • 4
    McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599-603.
  • 5
    Brugha R, Starling M, Walt G. GAVI, the first steps: lessons for the Global Fund. Lancet 2002; 359: 435-438.
  • 6
    Schreeder MT, Bender TR, McMahon BJ, Moser MR, Murphy BL, Sheller MF, et al. Prevalence of hepatitis-B in selected Alaskan Eskimo villages. Am J Epidemiol 1983; 118: 543-549.
  • 7
    Heyward WL, Lanier AP, Bender TR, Hardison HH, Dohan PH, McMahon BJ, et al. Primary hepatocellular-carcinoma in Alaska Natives, 1969-1979. Int J Cancer 1981; 28: 47-50.
  • 8
    McMahon BJ, Rhoades ER, Heyward WL, Tower E, Ritter D, Lanier AP, et al. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan Natives. Lancet 1987; 330: 1134-1136.
  • 9
    Mast EE, Margolis HS, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54: 1-31.
  • 10
    Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006; 28: 126-135.
  • 11
    CDC. Implementation of newborn hepatitis B vaccination—Worldwide, 2006. MMWR 2008; 57: 1249-1252.
  • 12
    McMahon BJ, Schoenberg S, Bulkow L, Wainwright RB, Fitzgerald MA, Parkinson AJ, et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives. Am J Epidemiol 1993; 138: 544-9.
  • 13
    Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133: 1452-7.
  • 14
    State of Alaska. Universal Infant Hepatitis B Immunization: A New Program is Launched. In: Division of Public Health Section of Epidemiology BN, ed. February 1, 1993.
  • 15
    Alaska So. Childhood Vaccination Recommendations Expanded. In: Division of Public Health EBN, ed. December 4, 1997.
  • 16
    State of Alaska. New School and Childcare Recommendations for Fall, 2001. In: Department of Health and Social Services, Division of Public Health, Section of Epidemiology, Bulletin No. 21. December 26, 2000.
  • 17
    McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. HEPATOLOGY 2000; 32: 842-846.
  • 18
    National Immunization Survey, Children 19-35 months, Data Tables. Accessed April 24, 2010, at
  • 19
    Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children — ten years of mass vaccination in Taiwan. JAMA 1996; 276: 906-908.
  • 20
    Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 2000; 181: 413-418.
  • 21
    Zhou YH, Wu C, Zhuang H. Vaccination against hepatitis B: the Chinese experience. Chin Med J 2009; 122: 98-102.
  • 22
    Mahoney FJ, Woodruff BA, Erben JJ, Coleman PJ, Reid EC, Schatz CG, et al. Effect of a hepatitis-B vaccination program on the prevalence of hepatitis-B virus-infection. J Infect Dis 1993; 167: 203-207.
  • 23
    Esteroff DT, Greenman JA, Heyward WL, McMahon BJ, Hardison HH, Bender TR. Increased prevalence of hepatitis B surface antigen in pregnant Alaska Eskimos. Circumpolar Health 1985; 84: 206-208.
  • 24
    Livingston SE, Bulkow LR, Homan CE, Snowball MM, Cagle HH, Negus SE, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D and F. Gastroenterology 2007; 133: 1452-1457.
  • 25
    Peterson NJ, Barrett DB, Bond WW, et al. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Environ Microbiol 1976; 32: 572-574.
  • 26
    Stroffolini T, Mele A, Tosti ME, Gallo G, Balocchini E, Ragni P, et al. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol 2000; 33: 980-985.
  • 27
    Mele A, Tosti ME, Mariano A, Pizzuti R, Ferro A, Borrini B, et al. Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges. Clin Infect Dis 2008; 46: 868-75.
  • 28
    McMahon BJ. The natural history of chronic hepatitis B virus infection. HEPATOLOGY 2009; 49: S45-S55.
  • 29
    Chang MH, Chen CJ, Lai MS, Hsu MH, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336: 1855-1859.
  • 30
    Wichajarn K, Kosalaraksa P, Wiangnon S. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 2008; 9: 507-10.
  • 31
    Goldstein ST, Zhou FJ, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 1329-1339.